Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Bristol-Myers Squibb (BMY) PT Raised to $80 at UBS
April 29, 2016 8:16 AM EDTUBS analyst Marc Goodman reiterated a Buy rating and boosted his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $80.00 (from $73.00) following results.
Goodman highlighted:
"Regarding Opdivo, mgt indicated that (1) it has >80% dollar share in US PD-1 category, and comparable shares in... More
